HIV 101: Initial Treatment: Preferred Regimens
| NNRTI-Based |
# pills/day |
Efavirenz*
+ (lamivudine [3TC] or emtricitabine [FTC])
+ (zidovudine [AZT, ZDF] or tenofovir DF [TDF]) |
2-3 |
| PI-Based |
# pills/day |
Lopinavir/ritonavir (Kaletra®)
+ (lamivudine [3TC] or emtricitabine [FTC])
+ (zidovudine [AZT, ZDF]) |
8-9 |
Advertisement
HIV 101: Initial Treatment: Alternative Regimens
| NNRTI-Based |
# pills/day |
Efavirenz*
+ (lamivudine [3TC] or emtricitabine [FTC])
+ (abacavir [ABC] or didanosine [ddI] or stavudine [d4T]) |
2-4 |
Nevirapine**
+ (lamivudine [3TC] or emtricitabine [FTC])
+ (zidovudine [ZDV] or stavudine [d4T] or didanosine
[ddI] or abacavir [ABC] or tenofovir [TDF]) |
3-6 |
| NRTI-Based |
# pills/day |
| Abacavir [ABC] + lamivudine [3TC] + zidovudine [ZDV]^
|
2 |
| PI-Based |
# pills/day |
Atazanavir
+ (lamivudine [3TC] or emtricitabine [FTC])
+ (zidovudine [ZDV] or stavudine [d4T] or abacavir [ABC] or didanosine [ddI]) or (tenofovir [TDF] + ritonavir [RTV] 100mg/d) |
3-6 |
Lopinavir/ritonavir (Kaletra)
+ (lamivudine [3TC] or emtricitabine [FTC])
+ (stavudine [d4T] or abacavir [ABC] or tenofovir [TDF] or didanosine [ddI]) |
7-10 |
Fosamprenavir or fosamprenavir/ritonavir or indinavir/
ritonavir or nelfinavir or saquinavir (hard- or soft-gel capsule)/ritonavir
+ (lamivudine [3TC] or emtricitabine [FTC])
+ (zidovudine [ZDV] or stavudine [d4T] or abacavir [ABC] or tenofovir [TDF] or didanosine [ddI]) |
5-15 |
* Avoid in pregnant women and women with high pregnancy potential.
** Because of higher rates of hepatotoxicity, nevirapine should not be initiated in women with pre-nevirapine CD4-T cell counts less than 250 cells/mm3 or men with CD4-T cell counts less than 400 cells/mm3, unless the benefit clearly outweighs the risk.
^ To be used only when a preferred or alternative NNRTI- or PI-based regimen cannot or should not be used as first-line theapy.
Tables adapted from DHHS. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. October 6, 2005. Last accessed November 16, 2005.
This article was provided by Brown Medical School. It is a part of the publication Infectious Diseases in Corrections Report.
Email
Print-Friendly
Glossary
PDF
